Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 446

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 446
---
 compensation programs. Actual compensation programs that New Profusa adopts following the completion of the business combination may differ materially from the existing and currently planned programs summarized or referred to in this discussion. Overview We have opted to comply with the executive compensation disclosure rules applicable to emerging growth companies as NorthView Acquisition Corp. is an emerging growth company. The scaled down disclosure rules are those applicable to “smaller reporting companies,” as such term is defined in the rules promulgated under the Securities Act. Such rules, in the context of an S -4Registration Statement, require compensation disclosure for Profusa’s principal executive officer and its two most highly compensated executive officers other than the principal executive officer whose total compensation for 2023 exceeded $100,000, who were serving as executive officers as of December 31, 2023 and who will continue with New Profusa. We refer to these individuals as “named executive officers.” For 2023, Ben Hwang, Chief Executive Officer and Chairman, was Profusa’s only “named executive officer.” Profusa only had one named executive officer who will continue with New Profusa. We expect that New Profusa’s executive compensation program will evolve to reflect its status as a newly publicly -tradedcompany, while still supporting New Profusa’s overall business and compensation objectives. 2023 Compensation of Named Executive Officer Cash Compensation Base salaries are intended to provide a level of compensation sufficient to attract and retain an effective management team, when considered in combination with the other components of the executive compensation program. In general, Profusa provides a base salary level designed to reflect the executive officer’s scope of responsibility and accountability. While cash bonuses have been provided on a discretionary basis in prior years, Dr. Hwang did not receive a cash bonus with respect to 2023. Equity Awards While Profusa maintains an equity compensation plan, during 2023, Dr. Hwang did not receive any equity awards with respect to Profusa and, as of December 31, 2023, Dr. Hwang did not hold any outstanding equity awards with respect to Profusa. 2023 Summary Compensation Table The following table shows information regarding the compensation of Dr. Hwang, our sole named executive officer, for services performed in the years ended December 31, 2023 and 2022.

| Name and Principal Position          |     | Year |     |  Salary 
     ($) |     | Bonus 
 ($)   |     | Option 
 Awards 
 ($)(1) |     | Stock  
 Awards 
 ($)    |     |